Eli Lilly-Backed Aktis Oncology Gets $317.7 Million in US IPO

Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 million in an initial public offering priced at the top of the marketed range.

The Boston-based firm sold 17.65 million shares at $18 each, according to a statement Thursday. The listing also drew interest from Eli Lilly for about $100 million shares, according to an earlier filing with the US Securities and Exchange Commission.